Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

Triple-negative breast cancer (TNBC) is among the most aggressive and lethal types of breast cancer, and currently available therapies have an unsatisfactory impact on patients' survival. The primary aim of this clinical trial is to evaluate efficacy in terms of Overall Response Rate (ORR) of atezolizumab plus cyclophosphamide and vinorelbine in first line patients with unresectable locally advanced or metastatic TNBC patients, previously treated with anti-programmed cell death ligand-1 (PD-L1) or anti-programmed cell death-1 (PD-1) - containing regimens, in the neoadjuvant/adjuvant setting.

NCT Number	NCT06690840
Lead Sponsor	European Institute of Oncology
Conditions	Triple Negative Breast Cancer
Enrollment	45 participants
Start Date	2025-03-06
Primary Completion	2026-12-15 (estimated)
Study Completion	2027-02-15 (estimated)
Updated on ClinicalTrials.gov	2026-01-05